Our in vitro results from experiments on apoptosis and NF-κB signaling reinforce the hypothesis that celastrol, and less potently resveratrol, can be used as adjuvant therapy for treatment of triple negative breast cancer since they showed inhibitory effects of NF-κB signaling and induction of apoptosis on the micromolar scale. This evidence concerns the gene NFKB1 and triple-negative breast carcinoma.